EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Deniz Işık iD, Oğuzcan Kınıkoğlu iD, Goncagül Akdağ iD, Yunus Emre Altıntaş, Ezgi Türkoğlu, Sedat Yildirim iD, Heves Sürmeli iD, Tuğba Başoğlu, Hatice Odabaş iD, Nedim Turan

Medicina · 2024

DOI: 10.3390/medicina60071088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, 2024. Verfasst von Deniz Işık und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms, Axitinib. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment and escape for metastatic renal cell carcinoma (RCC) has rapidly evolved, particularly with the integration of immune therapies into first-line regimens. However, optimal strategies following progression in first-line immunotherapy remain uncertain. This study aims to evaluate the efficacy and safety of axitinib and cabozantinib as third-line therapies after progression on nivolumab following first-line VEGF-TKI therapy.

Methods

Patients with metastatic RCC who progressed on prior nivolumab treatment after receiving first-line VEGF-TKI therapy were included. Data on patient characteristics, treatment regimens, response rates, progression-free survival (PFS), and overall survival (OS) were collected. Statistical analyses were conducted to assess the prognostic factors and treatment outcomes.

Results

A total of 46 patients were included who were predominantly male (83%) with clear-cell histology (89%). The median PFS on first-line TKI therapy was 10.2 months. All the patients received nivolumab as a second-line therapy, with a median of 12 cycles. The median second-line PFS was seven months. Third-line therapies included axitinib (24 patients) and cabozantinib (20 patients). The median PFS for axitinib and cabozantinib was six months, with comparable survival outcomes. The IMDC risk group and treatment tolerability were significant predictors of survival in multivariate analysis. Adverse events were manageable, with hypertension, fatigue, and diarrhea being the most common.

Conclusion

Axitinib and cabozantinib show promise as third-line therapies post-nivolumab progression in metastatic RCC, though prospective validation is warranted. This study underscores the need for further research to establish treatment standards in this evolving landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNivolumabKidney NeoplasmsAxitinibAnilidesPyridinesHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesTreatment OutcomeMolecular Targeted TherapyAged, 80 and overAntineoplastic Agents, ImmunologicalProgression-Free SurvivalProtein Kinase InhibitorsNeoplasm Metastasis

Stichwörter der Autor:innen

efficacy and toxicitynivolumabrenal cell carcinomatargeted therapy

Substanzen

NivolumabcabozantinibAxitinibAnilidesPyridinesAntineoplastic Agents, ImmunologicalProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.

ORCID-Profile: Deniz Işık, Oğuzcan Kınıkoğlu, Goncagül Akdağ, Sedat Yildirim, Heves Sürmeli, Hatice Odabaş

Zitieren

APA

Işık, D., Kınıkoğlu, O., Akdağ, G., Altıntaş, Y. E., Türkoğlu, E., Yildirim, S., Sürmeli, H., Başoğlu, T., Odabaş, H., & Turan, N. (2024). Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study. Medicina. https://doi.org/10.3390/medicina60071088

Vancouver

Işık D, Kınıkoğlu O, Akdağ G, Altıntaş YE, Türkoğlu E, Yildirim S, et al. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study. Medicina. 2024. doi:10.3390/medicina60071088

BibTeX
@article{Ik2024,
  author = {Işık, Deniz and Kınıkoğlu, Oğuzcan and Akdağ, Goncagül and Altıntaş, Yunus Emre and Türkoğlu, Ezgi and Yildirim, Sedat and Sürmeli, Heves and Başoğlu, Tuğba and Odabaş, Hatice and Turan, Nedim},
  title = {Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study},
  journal = {Medicina},
  year = {2024},
  doi = {10.3390/medicina60071088}
}
Kostenlos starten →